See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Vatican
Ukraine War
Volodymyr Zelenskyy
Olaf Scholz
Donald Trump
Elon Musk
Israel-Hamas Conflict
Vladimir Putin
Premier League
Baseball
Tennis
Published • loading... • Updated

Groundbreaking Bladder Cancer Trial Results: RemeGen's Treatment Doubles Standard Therapy Success Rate

Summary by stocktitan.net
Clinical data reveals RemeGen's DV combo therapy achieves 63.6% complete response in bladder cancer, surpassing traditional treatments with improved safety profile.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
pipelinereviewpipelinereview

RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer - Pipelinereview

YANTAI, China I February 15, 2025 I On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the latest efficacy and safety data from the phase II clinical trial (NCT05297552, Study ID: RC48-C017) of Disitamab Vedotin (DV) in combination Toripalimab as the neoad…

Read Full Article
stocktitan.netstocktitan.net

Groundbreaking Bladder Cancer Trial Results: RemeGen's Treatment Doubles Standard Therapy Success Rate

Clinical data reveals RemeGen's DV combo therapy achieves 63.6% complete response in bladder cancer, surpassing traditional treatments with improved safety profile.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Saturday, February 15, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Yantai

Yantai

News
For You
Search
BlindspotLocal